semaglutide cardiac protection FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular National Consensus on Semaglutide in
Description
Both Wegovy and Zepbound have warnings in their US prescribing information about the risk of suicidal behavior and ideation, noting that those risks have been reported in clinical trials with other chronic weight management products and recommending that patients be monitored for that risk
Ongoing Monitoring & Adjustments Regular check-ins allow providers to track progress, address side effects, and adjust treatment as needed
While insulin levels were not affected, plasma pancreatic peptide, glucagon, and acetaminophen levels were all reduced
This makes it an easy-to-navigate process
